Vertex Pharmaceuticals holds a near-monopoly in treating the underlying cause of cystic fibrosis, with a franchise of small-molecule drugs that transformed the disease and faces no meaningful competition. That cash flow funds a pipeline aimed at other serious conditions: non-opioid pain treatment, kidney disease, type 1 diabetes cell therapy, and a gene-editing partnership that produced one of the first approved CRISPR-based therapies. Founded in 1989, Vertex concentrates on diseases where biology is well understood and few or no options exist.